Spyre Therapeutics shares preclinical and early clinical data on three IBD antibodies at UEGW 2026
Spyre Therapeutics presented new mouse study results and early human data for its three inflammatory‑bowel‑disease antibodies—SPY001, SPY002 and SPY003—at United European Gastroenterology Week in Barcelona. The antibodies are being evaluated as single agents and in pairwise combinations in the Phase 2 SKYLINE platform trial. Silvio Danese, chair of the SKYLINE steering committee, said the company has demonstrated proof‑of‑concept and looks forward to combination results next year.
Why it matters
The proof‑of‑concept data may raise investor expectations for Spyre’s combination strategy and could influence the valuation of the company as the SKYLINE trial progresses, according to the company’s own press release ().
Key facts
- 1Spyre presented preclinical mouse data showing that combining its three antibodies improves efficacy over each alone (). stocktitan.net
- 2Clinical data for SPY001 (anti‑α4β7), SPY002 (anti‑TL1A) and SPY003 (anti‑IL‑23) were shown at the congress (). investing.com
- 3The antibodies are being tested as monotherapies and in pairwise combinations in the SKYLINE Phase 2 platform trial (). stocktitan.net
- 4Silvio Danese, professor at Vita‑Salute San Raffaele University and chair of the SKYLINE steering committee, delivered the oral presentation on Sunday (). investing.com
- 5A moderated poster on the three antibodies in humanized mice was scheduled for Monday (). investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.